BIONEUTRA GLOBAL CORPORATION |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1 CAD | 0.00% |
|
0.00% | +400.00% |
| 04-26 | BioNeutra Global Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-08 | BioNeutra Global Corporation Appoints Stephen Jakeway as Chief Operating Officer | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 26.19 | 13.75 | 8.593 | 7.896 | 0.929 | 0.934 |
| Enterprise Value (EV) 1 | 33.63 | 20.8 | 14.73 | 13.95 | 7.212 | 6.684 |
| P/E ratio | 8.44 x | -1.11 x | -2.31 x | -2.79 x | -0.32 x | -0.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.69 x | 0.36 x | 0.36 x | 0.51 x | 0.07 x | 0.08 x |
| EV / Revenue | 0.89 x | 0.55 x | 0.61 x | 0.91 x | 0.54 x | 0.59 x |
| EV / EBITDA | 10.1 x | -2.81 x | -16.1 x | -6.53 x | -5.11 x | -160 x |
| EV / FCF | -18.2 x | 3.25 x | 5.57 x | -217 x | 4.83 x | 4.15 x |
| FCF Yield | -5.51% | 30.7% | 17.9% | -0.46% | 20.7% | 24.1% |
| Price to Book | 1.45 x | 2.93 x | 12.3 x | -7.64 x | -0.25 x | -0.15 x |
| Nbr of stocks (in thousands) | 45,950 | 45,820 | 46,449 | 46,449 | 46,449 | 46,699 |
| Reference price 2 | 0.5700 | 0.3000 | 0.1850 | 0.1700 | 0.0200 | 0.0200 |
| Announcement Date | 19-04-30 | 20-06-16 | 21-04-30 | 22-04-28 | 23-04-25 | 24-04-26 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 37.72 | 37.7 | 24.12 | 15.4 | 13.39 | 11.38 |
| EBITDA 1 | 3.321 | -7.406 | -0.9153 | -2.135 | -1.41 | -0.0417 |
| EBIT 1 | 2.399 | -9.676 | -2.702 | -3.404 | -2.467 | -1.1 |
| Operating Margin | 6.36% | -25.67% | -11.2% | -22.1% | -18.42% | -9.66% |
| Earnings before Tax (EBT) 1 | 3.573 | -13.02 | -3.772 | -2.83 | -2.921 | -2.108 |
| Net income 1 | 3.103 | -12.44 | -3.707 | -2.83 | -2.921 | -2.108 |
| Net margin | 8.23% | -33.01% | -15.37% | -18.37% | -21.82% | -18.52% |
| EPS 2 | 0.0675 | -0.2700 | -0.0800 | -0.0609 | -0.0629 | -0.0500 |
| Free Cash Flow 1 | -1.852 | 6.395 | 2.645 | -0.0643 | 1.492 | 1.612 |
| FCF margin | -4.91% | 16.96% | 10.97% | -0.42% | 11.14% | 14.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-04-30 | 20-06-16 | 21-04-30 | 22-04-28 | 23-04-25 | 24-04-26 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 7.44 | 7.06 | 6.14 | 6.05 | 6.28 | 5.75 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.24 x | -0.9529 x | -6.709 x | -2.836 x | -4.455 x | -138 x |
| Free Cash Flow 1 | -1.85 | 6.39 | 2.64 | -0.06 | 1.49 | 1.61 |
| ROE (net income / shareholders' equity) | 19.4% | -109% | -136% | 1,700% | 122% | 42.4% |
| ROA (Net income/ Total Assets) | 4.23% | -16.3% | -5.85% | -9.51% | -7.54% | -3.87% |
| Assets 1 | 73.43 | 76.14 | 63.34 | 29.77 | 38.72 | 54.48 |
| Book Value Per Share 2 | 0.3900 | 0.1000 | 0.0200 | -0.0200 | -0.0800 | -0.1300 |
| Cash Flow per Share 2 | 0.0300 | 0.0100 | 0.0200 | 0.0200 | 0.0200 | 0.0400 |
| Capex 1 | 0.77 | 0.14 | 0.03 | 0.28 | 0.12 | 0.02 |
| Capex / Sales | 2.04% | 0.38% | 0.12% | 1.8% | 0.89% | 0.17% |
| Announcement Date | 19-04-30 | 20-06-16 | 21-04-30 | 22-04-28 | 23-04-25 | 24-04-26 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +400.00% | 3.39M | |
| -2.39% | 272B | |
| -1.88% | 94.16B | |
| -2.64% | 43.36B | |
| +1.40% | 41B | |
| +9.82% | 40.46B | |
| +8.18% | 39.67B | |
| -13.58% | 30.87B | |
| -4.77% | 29.02B | |
| +14.15% | 25.11B |
- Stock Market
- Equities
- BGA Stock
- Financials BioNeutra Global Corporation